How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/anemia-in-chronic-kidney-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Anemia in chronic kidney disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anemia in chronic kidney disease (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Anemia in chronic kidney disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Jesduvroq	DAPRODUSTAT	GSK	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	Egl nine homolog 1	2023-01-01
Evrenzo	ROXADUSTAT	Astellas Pharma Europe B.V.		Thyroid hormone receptor beta	2021-01-01
Silapo	EPOETIN ZETA	Hospira UK Limited		Erythropoietin receptor	2007-01-01
Mircera	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	Hoffman-La Roche		erythropoietin receptor	2007-01-01
Neorecormon	EPOETIN BETA	Roche Registration Limited		Erythropoietin receptor	1997-01-01
Epogen	Epoetin Alfa-Epbx	Amgen	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor	1989-01-01
Epogen	EPOETIN ALFA	Amgen	Erythropoiesis-stimulating Agent	Erythropoietin receptor	1989-01-01
Nandrolone Decanoate	NANDROLONE DECANOATE	Woodward Specl	Androgen	Sex hormone-binding globulin	1962-01-01
Enaroy	ENARODUSTAT	Japan Tabacco		Egl nine homolog 1
Erythropoietin	Erythropoietin	Nanjing First Hospital, Nanjing Medical University		Erythropoietin receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Amgen · 2 drugs in Anemia in chronic kidney disease
Astellas Pharma Europe B.V. · 1 drug in Anemia in chronic kidney disease
Centre Hospitalier Universitaire, Amiens · 1 drug in Anemia in chronic kidney disease
GSK · 1 drug in Anemia in chronic kidney disease
Hoffman-La Roche · 1 drug in Anemia in chronic kidney disease
Hospira UK Limited · 1 drug in Anemia in chronic kidney disease
Japan Tabacco · 1 drug in Anemia in chronic kidney disease
Johns Hopkins University · 1 drug in Anemia in chronic kidney disease
Nanjing First Hospital, Nanjing Medical University · 1 drug in Anemia in chronic kidney disease
Roche Registration Limited · 1 drug in Anemia in chronic kidney disease
Samsung Medical Center · 1 drug in Anemia in chronic kidney disease
University of Louisville · 1 drug in Anemia in chronic kidney disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Anemia in chronic kidney disease:

Cite this brief

Drug Landscape (2026). Anemia in chronic kidney disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/anemia-in-chronic-kidney-disease. Accessed 2026-06-10.

Anemia in chronic kidney disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing